英派药业-B(07630)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

07630 英派药业-B

未开盘 09-10 16:08:42

11.620

-0.920

-7.34%

最高12.870	最低11.610	成交量161.20万
今开12.800	昨收12.540	日振幅10.05%
总市值32.82亿	流通市值32.82亿	总股本2.82亿
成交额1,966万	换手率0.57%	流通股本2.82亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"07630","market":"HK","secType":"STK","nameCN":"英派药业-B","latestPrice":11.62,"timestamp":1789027722313,"preClose":12.54,"halted":0,"volume":1612000,"delay":0,"changeRate":-0.0733652312599681,"floatShares":282461530,"shares":282461530,"eps":-1.294715,"marketStatus":"未开盘","change":-0.92,"latestTime":"09-10 16:08:42","open":12.8,"high":12.87,"low":11.61,"amount":19662852,"amplitude":0.100478,"askPrice":11.85,"askSize":1000,"bidPrice":11.62,"bidSize":15600,"shortable":0,"etf":0,"ttmEps":-1.052,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1789090200000},"marketStatusCode":0,"adr":0,"listingDate":1778601600000,"exchange":"SEHK","adjPreClose":12.54,"openAndCloseTimeList":[[1789003800000,1789012800000],[1789016400000,1789027200000]],"volumeRatio":1.246229,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/07630/wiki","defaultTab":"wiki","newsList":[{"id":"2665339957","title":"英派药业-B(07630)获纳入沪港通及深港通证券名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2665339957","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665339957?lang=zh_cn&edition=full","pubTime":"2026-09-07 12:26","pubTimestamp":1788755188,"startTime":"0","endTime":"0","summary":"智通财经APP讯，英派药业-B(07630)发布公告，根据上海证券交易所及深圳证券交易所分别发出的公告，公司H股已获纳入沪港通及深港通合资格证券名单，自2026年9月7日起生效。公司H股获纳入沪港通及深港通合资格证券名单后，中国内地合资格投资者将可透过上海证券交易所及深圳证券交易所直接投资公司H股。公司认为，获纳入沪港通及深港通将有利于进一步扩大公司的投资者基础，并有望提升公司H股的交易流动性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492657.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","161027","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118211105","title":"英派药业-B（07630）H股纳入沪深港通合资格名单 将于2026年9月7日生效","url":"https://stock-news.laohu8.com/highlight/detail?id=1118211105","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118211105?lang=zh_cn&edition=full","pubTime":"2026-09-07 12:11","pubTimestamp":1788754275,"startTime":"0","endTime":"0","summary":"南京英派药业股份有限公司9月7日发布自愿公告称，公司H股已被上海证券交易所及深圳证券交易所纳入沪港通及深港通合资格证券名单，生效日期为2026年9月7日。\\n\\n公告指出，H股被纳入相关名单后，中国内地合资格投资者可通过沪股通或深股通渠道直接买卖英派药业-B的H股。公司认为，这一安排有望扩大其投资者基础，并提升H股交易流动性。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664319063","title":"英派药业(07630)正式纳入港股通 打开内地投资者参与通道","url":"https://stock-news.laohu8.com/highlight/detail?id=2664319063","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664319063?lang=zh_cn&edition=full","pubTime":"2026-09-04 20:05","pubTimestamp":1788523535,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，上交所9月4日盘后发布通知，根据《上海证券交易所沪港通业务实施办法》有关规定，英派药业(07630)正式调入港股通标的证券名单，该调整将于9月7日(周一)起生效。这意味着内地投资者自此可通过沪深港通直接买卖英派药业，正式解锁南向资金。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492309.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["FLHK","07630","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184000576","title":"英派药业-B发布2026年8月股份变动月报表，股本保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1184000576","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184000576?lang=zh_cn&edition=full","pubTime":"2026-09-04 16:48","pubTimestamp":1788511685,"startTime":"0","endTime":"0","summary":"2026年9月4日，英派药业-B（股票代码：07630）发布2026年8月股份变动月报表。公告显示，截至2026年8月31日，公司注册股本为人民币282,461,530元，股票类型为普通股H股，面值人民币1元。本月初和月末的已发行股份数均为282,461,530股，库藏股份为0股，股本总数未发生变化。\n公司同时披露，报告期内未进行新的股份发行、购回、注销或库藏股变动，也不存在任何股份期权、权证或可换股票据的行使或失效情形。截至期末，公司符合香港联交所相关上市规则的最低公众持股量要求。\n公告由执行董事兼首席执行官蔡遂雄签署，公司重申将继续严格遵守香港联交所《上市规则》及相关法律法规的各项规定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664797918","title":"蔡遂雄增持英派药业-B(07630)10万股 每股作价约14.61港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2664797918","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664797918?lang=zh_cn&edition=full","pubTime":"2026-09-03 19:30","pubTimestamp":1788435009,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，9月1日，蔡遂雄增持英派药业-B(07630)10万股，每股作价14.6105港元，总金额为146.105万港元。增持后最新持股数目约为1854.09万股，最新持股比例为6.56%。补充资料：The capacity in which shares are held in box 24 are set out in box 27.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491662.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["07630","EWH","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163390150","title":"英派药业-B：蔡遂雄增持，好仓比例升至6.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=1163390150","media":"港股披露","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1163390150?lang=zh_cn&edition=full","pubTime":"2026-09-03 17:50","pubTimestamp":1788429032,"startTime":"0","endTime":"0","summary":"蔡遂雄于2026年9月1日以每股均价14.6105港元买入英派药业-B股份10.00万股，涉资约146.10万港元。蔡遂雄此次增持前持有英派药业-B好仓1844.09万股，占比6.53%；增持后持股量为1854.09万股，好仓比例升至6.56%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664982473","title":"港股异动 | 英派药业-B(07630)涨近13% 核心产品塞纳帕利快速放量 获纳入恒生综指有望入通","url":"https://stock-news.laohu8.com/highlight/detail?id=2664982473","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664982473?lang=zh_cn&edition=full","pubTime":"2026-09-03 15:07","pubTimestamp":1788419276,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，英派药业-B涨近13%，截至发稿，涨11.14%，报14.87港元，成交额514.81万港元。消息面上，英派药业今早公告，董事会获公司执行董事兼首席执行官蔡遂雄告知，其近期已于公开市场购买合共10万股公司普通股，每股股份平均价格为约14.6105港元，占公司已发行股份总数之约0.035%。今年上半年，英派药业实现收入1.05亿元，同比增长316.8%；净亏损则同比收窄29.5%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491436.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["07630","BK1161","KCAI","BK4585","BK4588","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664703842","title":"英派药业-B(07630.HK)获执行董事兼首席执行官蔡遂雄增持10万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2664703842","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664703842?lang=zh_cn&edition=full","pubTime":"2026-09-03 08:09","pubTimestamp":1788394151,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["07630","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121979207","title":"英派药业-B（07630）CEO蔡遂雄增持10万股 持股比例升至6.564%","url":"https://stock-news.laohu8.com/highlight/detail?id=1121979207","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121979207?lang=zh_cn&edition=full","pubTime":"2026-09-03 08:06","pubTimestamp":1788393971,"startTime":"0","endTime":"0","summary":"南京英派药业股份有限公司（英派药业-B，07630）9月3日自愿公告称，执行董事兼首席执行官蔡遂雄博士近期在公开市场合计买入100,000股公司普通股，每股平均价格约14.6105港元，增持股份占公司已发行股份总数约0.035%。\\n\\n本次增持后，蔡遂雄博士合共持有18,540,884股公司股份，占截至公告日期已发行股本总额约6.564%。\\n\\n公告指出，蔡遂雄博士对公司整体发展前景及潜在增长保持信心，并在遵守适用法律及监管规定的前提下，不排除未来继续增持股份的可能性。\\n\\n公司提醒股东及潜在投资者在买卖公司证券时保持审慎。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167736412","title":"英派药业-B2026年上半年营收1.05亿元，经调整净亏损0.21亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1167736412","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167736412?lang=zh_cn&edition=full","pubTime":"2026-08-31 16:38","pubTimestamp":1788165480,"startTime":"0","endTime":"0","summary":"2026年上半年，英派药业-B实现营收1.05亿元，同比增长316.8%。同期，经调整净亏损为0.21亿元，较去年同期的0.56亿元显著收窄62.6%。公司毛利率为90.8%，上年同期为97.7%；经营活动所得现金流净额为0.24亿元，较上年同期的0.30亿元减少0.06亿元。销售及分销开支为0.23亿元，上年同期该指标约为0.05亿元。英派药业-B执行董事兼首席执行官蔡遂雄博士：“本人谨代表董事会衷心感谢股东及业务合作伙伴一直以来的信任及支持，亦感谢雇员的勤勉、奉献、忠诚及诚信。”","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"英派药业-B2026年上半年营收1.05亿元，经调整净亏损0.21亿元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663507581","title":"英派药业-B(07630.HK)发布中期业绩 收入1.05亿元 同比增长316.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663507581","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663507581?lang=zh_cn&edition=full","pubTime":"2026-08-31 16:34","pubTimestamp":1788165294,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661241386","title":"英派药业-B(07630.HK)获纳入恒生综合指数成份股","url":"https://stock-news.laohu8.com/highlight/detail?id=2661241386","media":"中金财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661241386?lang=zh_cn&edition=full","pubTime":"2026-08-24 07:57","pubTimestamp":1787529422,"startTime":"0","endTime":"0","summary":"格隆汇8月24日丨英派药业-B(07630.HK)发布公告，其已获恒生指数有限公司选定并将纳入恒生综合指数成份股，自2026年9月7日起生效。获纳入恒生综合指数成份股后，公司股份预期将符合纳入沪港通及深港通交易的标准。沪港通及深港通是香港与中国内地资本市场投资者进行股票交易及投资的渠道。\r\n\r\n　　公司认为，其获纳入恒生综合指数成份股，表明国际资本市场对公司的行业地位、经营表现及整体价值的认可。预期此举将提升股票的交易流动性，扩大并多元化股东基础，并有助于公司的长期持续增长。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260824/32344064.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["07630","HSCI","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661601562","title":"英派药业-B(07630)获纳入恒生综合指数 有望成为港股通标的","url":"https://stock-news.laohu8.com/highlight/detail?id=2661601562","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661601562?lang=zh_cn&edition=full","pubTime":"2026-08-21 19:54","pubTimestamp":1787313252,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，2026年8月21日，恒生指数公司公布截至2026年6月30日之恒生指数系列季度检讨结果，其中英派药业-B获纳入恒生综合指数。恒生综合指数变动将于9月4日(星期五)收市后实施并于9月7日(星期一)起生效，届时沪深交易所会相应调整港股通可投资标的范围。英派药业有可能被调入港股通，因其满足了包括市值、流动性等在内的一系列标准。英派药业今日大涨超10%，收报13.46港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1483572.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["FLHK","07630","BK1161","HSCI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101909160","title":"英派药业-B定于8月31日召开董事会审议2026年中期未审计业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1101909160","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1101909160?lang=zh_cn&edition=full","pubTime":"2026-08-19 16:42","pubTimestamp":1787128928,"startTime":"0","endTime":"0","summary":"南京英派药业股份有限公司（07630）8月19日在港交所公告称，公司董事会将于2026年8月31日（星期一）召开会议，审议并批准公司及其附属公司截至2026年6月30日止六个月的未经审计中期业绩及其发布事宜。\n公告显示，截至本公告日期，公司董事会由3名执行董事、3名非执行董事及3名独立非执行董事组成。执行董事包括蔡遂雄博士（兼首席执行官）、田野博士及马宁女士；非执行董事为徐聪博士、Qiang Xu博士及刘涛先生；独立非执行董事为郭明博士、萧志雄先生及邵黎明博士。\n公司提醒投资者关注相关业绩公告发布时间，并据此评估可能产生的影响。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659118951","title":"港股异动 | 英派药业-B(07630)涨超3% 预期中期取得亏损同比减少约22%至37% 已将IMP2794提名为PPC","url":"https://stock-news.laohu8.com/highlight/detail?id=2659118951","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659118951?lang=zh_cn&edition=full","pubTime":"2026-08-14 13:48","pubTimestamp":1786686502,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，英派药业-B涨超3%，截至发稿，涨2.64%，报12.43港元，成交额306.36万港元。此外，英派药业-B公告称，公司已将IMP2794提名为临床前候选化合物，为一款 KAT6A特异性降解PROTAC。IMP2794是英派药业依托其自有的靶向蛋白降解平台发现的首个PCC。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479923.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK4588","07630","BK4585","BK1161","PPC","BK4212","KCAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111945504","title":"英派药业-B（07630）首款自研KAT6A高特异性PROTAC IMP2794获选为临床前候选化合物","url":"https://stock-news.laohu8.com/highlight/detail?id=1111945504","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111945504?lang=zh_cn&edition=full","pubTime":"2026-08-12 17:20","pubTimestamp":1786526458,"startTime":"0","endTime":"0","summary":"2026年8月12日，英派药业-B公布，其已正式将IMP2794提名为临床前候选化合物。IMP2794为一款针对KAT6A的高特异性蛋白降解靶向嵌合体，系公司依托自有靶向蛋白降解平台发现的首个PCC。公告披露，IMP2794可高效、选择性地降解KAT6A，对同源蛋白KAT6B的选择性超过1,000倍。英派药业-B提醒，根据香港联合交易所有限公司证券上市规则第18A.05条，公司无法保证最终能够成功开发、制造及／或商业化IMP2794。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658780479","title":"英派药业-B(07630)提名IMP2794为临床前候选化合物(PCC) 一款源自公司自有靶向蛋白降解平台的KAT6A高特异性PROTAC","url":"https://stock-news.laohu8.com/highlight/detail?id=2658780479","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658780479?lang=zh_cn&edition=full","pubTime":"2026-08-12 17:17","pubTimestamp":1786526237,"startTime":"0","endTime":"0","summary":"智通财经APP讯，英派药业-B 发布公告，英派药业已将IMP2794提名为临床前候选化合物，为一款 KAT6A特异性降解PROTAC。IMP2794是英派药业依托其自有的靶向蛋白降解平台发现的首个PCC。IMP2794是一种高效且选择性作用于KAT6A的降解剂，对KAT6B的选择性超过1000倍。IMP2794在敏感、非敏感乳腺癌CDX模型中均展现出优异的体内抗肿瘤效果。同时，对KAT6B的抑制与潜在的血液毒性相关。公司已建立依托E3配体库与连接子库的降解平台，可快速组装口服生物利用度优异的PROTAC分子。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479011.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"英派药业-B(07630)提名IMP2794为临床前候选化合物(PCC) 一款源自公司自有靶向蛋白降解平台的KAT6A高特异性PROTAC","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2658911994","title":"营收暴增无阻英派药业继续亏损：预计上半年减亏三成左右！股价早已破发","url":"https://stock-news.laohu8.com/highlight/detail?id=2658911994","media":"深圳商报·读创","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658911994?lang=zh_cn&edition=full","pubTime":"2026-08-11 23:03","pubTimestamp":1786460583,"startTime":"0","endTime":"0","summary":"8月11日，英派药业(07630.HK)发布盈利预告，公司预计2026年上半年收入约9470万元至1.16亿元，较去年同期约2520万元增长约276%至359%；预计期内亏损约8170万元至9990万元，较去年同期约1.29亿元减少约22%至37%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608113838249182.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608113838249182.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["EIKN","07630","BK1161","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170386983","title":"英派药业-B预计中期营收最高增逾三倍 亏损显著收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=1170386983","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1170386983?lang=zh_cn&edition=full","pubTime":"2026-08-11 16:47","pubTimestamp":1786438063,"startTime":"0","endTime":"0","summary":"英派药业-B8月11日发布盈利预告称，预计截至2026年6月30日止六个月的收入约94.7百万元至约1.16亿元，较2025年同期的25.2百万元增长约276%至359%。同期公司预计录得期内亏损约81.7百万元至99.9百万元，较上一年度同期的128.7百万元减少约37%至22%。\\n\\n英派药业-B预计将在2026年8月公布中期业绩。公司提醒投资者在买卖公司证券时保持审慎。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658899307","title":"英派药业-B(07630.HK)预期中期取得亏损约8170万元至9990万元 同比减少约22%至37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658899307","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658899307?lang=zh_cn&edition=full","pubTime":"2026-08-11 16:47","pubTimestamp":1786438054,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["07630","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.impacttherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.2243},{"period":"1month","weight":-0.1143},{"period":"3month","weight":-0.6808},{"period":"6month","weight":-0.4219},{"period":"ytd","weight":-0.4219}],"compareEarnings":[{"period":"1week","weight":-0.0103},{"period":"1month","weight":-0.0272},{"period":"3month","weight":0.0096},{"period":"6month","weight":-0.0201},{"period":"1year","weight":-0.0475},{"period":"ytd","weight":-0.0264}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"南京英派药业股份有限公司是一家主要从事生物技术研发和商业化的中国公司。该公司处于商业化阶段。该公司致力于在全球范围内推进基于合成致死（SL）机制的精准抗癌疗法。该公司自主研发的核心产品塞纳帕利已在中国获批上市，作为卵巢癌（OC）一线维持疗法。该公司正在研发的产品管线包PARP1/2、PARP1、ATR、WEE1、PKMYT1/WEE1、DHX9、ATM、USP1及CHK1/2等。","exchange":"SEHK","name":"英派药业-B","nameEN":"IMPACT THERAP-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"英派药业-B(07630)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供英派药业-B(07630)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"英派药业-B,07630,英派药业-B股票,英派药业-B股票老虎,英派药业-B股票老虎国际,英派药业-B行情,英派药业-B股票行情,英派药业-B股价,英派药业-B股市,英派药业-B股票价格,英派药业-B股票交易,英派药业-B股票购买,英派药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"英派药业-B(07630)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供英派药业-B(07630)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}